Lured By Its Discovery Platform And Pipeline, Amgen Bids For Nuevolution

Amgen offered to buy its Scandinavian discovery partner for $166.8m to gain access to Nuevolution’s DNA-encoded drug discovery platform and nascent pipeline.

Fish
Amgen’s $166.8m Offer Backed By Nuevolution Board And Key Shareholders • Source: Shutterstock

Clearly impressed with their ongoing drug discovery collaboration, Amgen Inc. has now offered to buy Nuevolution AS for $166.8m in cash, representing at SEK32.5 ($3.37) per share a premium of 169% to the biotech’s closing price on 21 May, the day before the offer was announced, and which is being unanimously recommended by the Copenhagen-headquartered group board and main shareholders.

Founded in 2001, Nuevolution is an innovator in small-molecule drug discovery. Its internally developed DNA-encoded drug discovery platform, Chemetics, has...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Finance Watch: Two New Venture Capital Funds Provide $600m For Biopharma

 
• By 

Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.